Amgen Announces Appointment Of Greg C. Garland To Board Of Directors
THOUSAND OAKS, Calif., Oct. 16, 2013
THOUSAND OAKS, Calif., Oct. 16, 2013 /PRNewswire/ --Amgen (NASDAQ: AMGN)
today announced the appointment of Greg C. Garland, chairman, president and
chief executive officer of Phillips 66, to its Board of Directors.
"We are pleased to welcome Greg Garland to the Amgen Board. In addition to his
leadership experiences as a chief executive officer, Greg brings more than 30
years of international experience in a highly regulated industry," said Robert
A. Bradway, chairman and chief executive officer of Amgen. "At a time when
Amgen is expanding its global presence to serve more patients, we look forward
to Greg's contributions to the Board."
Mr. Garland will serve on the Governance andNominating Committee and the
Audit Committee of the Board. Following the appointment of Mr. Garland, the
Board on Oct. 16, 2013, will comprise 13 directors, 12 of whom are
Greg C. Garland
Mr. Garland, 55, currently serves as the Chairman, President and Chief
Executive Officer of Phillips 66, an energy manufacturing and logistics
company with midstream, chemical, refining and marketing and specialties
businesses created through the repositioning of ConocoPhillips, having held
this position since April 2012. Mr. Garland serves on the Executive Committee
of Phillips 66. Prior to Phillips 66, Mr. Garland served as Senior Vice
President, Exploration and Production, Americas of ConocoPhillips from 2010 to
April 2012. He was President and Chief Executive Officer of Chevron Phillips
Chemical Company (now a joint venture between Phillips 66 and Chevron) from
2008 to 2010 and Senior Vice President of Planning and Specialty Chemicals
from 2000 to 2008. Mr. Garland served in various positions at Phillips
Petroleum Company from 1980 to 2000. Mr. Garland is a member of the
Engineering Advisory Board for Texas A&M University.
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on
CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)
Press spacebar to pause and continue. Press esc to stop.